Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas [ChIP-Seq]

ABSTRACT: H3.3G34R/V hemispheric gliomas carry a dismal prognosis as current treatments including radio/chemotherapy are not curative. We undertook a systematic and comprehensive epigenetic approach to define therapeutic dependencies in H3.3G34R/V gliomas.

ORGANISM(S): Mus musculus

PROVIDER: GSE161287 | GEO | 2021/12/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas [RNA-Seq]

Project description:H3.3G34R/V hemispheric gliomas carrya dismal prognosisas current treatments including radio/chemotherapy are not curative. We undertook a systematic and comprehensive epigenetic approach to define therapeutic dependenciesin H3.3G34R/V gliomas.

2021-12-15 | GSE161288 | GEO

Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas

Project description:Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas

| PRJNA676134 | ENA

Single-cell/single-nucleus RNA-seq of diffuse hemispheric gliomas, H3G34-mutant.

Project description:As part of a multi-omics and CRISPR/Cas9-screen based study to extensively characterize the molecular basis of diffuse hemispheric gliomas, H3G34-mutant (DHG-H3G34), we applied single-cell/single-nucleus RNA-sequencing to a patient cohort of 9 fresh and frozen untreated DHG-H3G34.

2024-07-30 | GSE162989 | GEO

Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-12-15 | GSE161289 | GEO

Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas [ChIP-Seq]

Project description:Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas [ChIP-Seq]

| PRJNA676136 | ENA

Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas [RNA-Seq]

Project description:Epigenetically defined therapeutic targeting in H3G34R/V high-grade gliomas [RNA-Seq]

| PRJNA676137 | ENA

Circulating microRNA profiling in diffuse intrinsic pontine gliomas

Project description:Diffuse midline glioma (DMG) identifies gliomas originating in the thalami, brainstem, cerebellum and spine. Within this entity, tumours that infiltrate the pons, called diffuse intrinsic pontine gliomas (DIPGs), have a rapid onset and devastating neurological symptoms. Radiotherapy is the only intervention that is able to modify the disease course, albeit not in a curative way. In recent years, liquid biopsies have represented the next step in clinical diagnostics due to their easily accessible nature. The purpose of this study is to profile circulating miRNA expression to disclose a potential prognostic signature with clinical impact.

2022-12-21 | GSE160249 | GEO

Histone H3.3G34-mutant interneuron progenitors co-opt PDGFRA for gliomagenesis

Project description:Histone H3.3 glycine 34 to arginine/valine (H3.3G34R/V) mutations occur in deadly hemispheric high-grade gliomas. These tumors show exquisite regional and temporal specificity, suggesting a developmental context permissive to the effects of G34R/V mutations. Here we present the molecular landscape of G34R/V gliomas (n = 83) and show that ~50% bear activating mutations in PDGFRA, with strong selection pressure for PDGFRAMUT clones at recurrence. We show that G34R/V tumors arise in interneuron progenitors of the foetal ventral forebrain, expressing GSX2 and the DLX family of homeobox transcription factors, where terminal neuronal differentiation is impaired through aberrant G34R/V-mediated H3K27me3. Frequent co-occurrence of G34R/V & PDGFRAMUT is facilitated in this interneuron lineage-of-origin as PDGFRA forms an aberrant chromatin loop with the adjacent GSX2, hijacking its active chromatin conformation. At the single-cell level, G34R/V tumors entirely lack oligodendroglial transcriptional programs prominent in other glioma entities, and instead harbour dual neuronal and astroglial compartments. CRISPR-removal of H3.3G34R/V does not impact tumorigenicity suggesting this mutation becomes dispensable, while PDGFRAMUT are potently oncogenic regardless of G34 mutation. Collectively, our results suggest that G34R/V gliomas arise in foetal interneuron progenitors unable to terminally differentiate, enabling co-option of PDGFRA through inappropriate expression and activating mutations to promote gliogenesis and oncogenicity. Reliance on PDGFRA for oncogenesis may be of therapeutic opportunity in G34R/V glioma.

2020-11-30 | GSE146731 | GEO

Human ESC-based modeling of H3.3G34R-mutant high grade glioma

Project description:H3.3G34R-mutant gliomas are lethal tumors of the cerebral hemispheres, with unknown mechanisms of topographic specificity and tumorigenicity. We developed a human embryonic stem cell (hESC)-based model of H3.3G34R-mutant glioma that recapitulates the anatomical and genetic characteristics of the patient tumors.

2021-02-25 | GSE147543 | GEO

Proteomic analysis of IDHmut gliomas suggests novel classification with greater separation than 1p/19q codeletion status

Project description:Glial cell-derived brain tumors (gliomas) are devastating diseases without effective curative therapies. Gliomas are classified according to various schemes including the cancer-initiating cell type, World Health Organization tumor grades, and genetic markers such as Isocitrate dehydrogenase (IDH) mutations and chromosomal 1p/19q codeletion status. Genomics, transcriptomics and methylomics approaches are emerging as powerful means to refine classification. However, various aspects of cancer biology are solely reflected on the proteomelevel. Here, we employ mass spectrometry (MS) to characterize the proteomes and phospho-proteomes of IDHmut glioma entities with and without 1p/19q codeletion, IDHwt gliomas and control tissue from a total of 42 patients. Our data-dependent acquisition MS workflow on average quantifies more than 5000 proteins and 3000 phospho-sites per sample of formalin-fixed paraffin-embedded (FFPE) brain sections. The tumor proteomes reflected genetic alterations such as the loss of chromosome 1p/19q proteins, the loss of ATRX in non-codeletion IDHmut glioma, and the frequent loss and amplification of chromosomes 10 and 7, respectively,in IDH-wild type glioma. Nevertheless, 1p/19q codeletion status was not the major determinant of IDHmut glioma proteomes. Instead, the proteome profiles suggest an alternative classification of IDHmut gliomas that correlates with the loss of mitochondrial DNA-encoded proteins, the abundance of respiratory chain proteins, a distinct tumor suppressor and oncoprotein profile, an extracellular matrix signature, and alterations in the phospho-proteome. Moreover, the glioma association of numerous proteins implicated in other cancers by this dataset provides a resource for further mechanistic investigation of glioma genesis and progression.

2022-11-09 | PXD024427 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data